CS
ANVS icon

Cannell & Spears’s Annovis Bio ANVS Stock Holding History

Cannell & Spears’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$30K – 395
2025
Q1 		$30K Hold
20,000
– – ﹤0.01% 390
2024
Q4 		$101K Hold
20,000
– – ﹤0.01% 382
2024
Q3 		$161K Buy
20,000
+5,000
+33% +$46.8K ﹤0.01% 389
2024
Q2 		$86.4K Hold
15,000
– – ﹤0.01% 356
2024
Q1 		$179K Buy
+15,000
New +$164K ﹤0.01% 367

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cannell & Spears's ANVS Position: Q2 2025 in Review

Cannell & Spears sold out of Annovis Bio (ANVS) in Q2 2025, closing a stake of 20,000 shares — an estimated $30K sold.

Cannell & Spears first reported a position in ANVS in Q1 2024 and held it in 5 quarters. The position peaked at $179K in Q1 2024. 42 funds tracked by Wall St. Rank hold ANVS as of Q2 2025.

  • Cannell & Spears reported no remaining Annovis Bio position as of Q2 2025 after selling out during the quarter.
  • Cannell & Spears sold 20,000 Annovis Bio shares in Q2 2025, an estimated $30K.
  • Cannell & Spears first reported a position in Annovis Bio in Q1 2024 and held it in 5 quarters.
  • Cannell & Spears's Annovis Bio position peaked at $179K in Q1 2024.
  • 42 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2025.

Based on Cannell & Spears's 13F filing for Q2 2025, filed 14 Aug 2025.